About IMMUNOTECH-B Company

The company is a leading cellular immunotherapy biomedical company in China. It has focused on the development and commercialization of T-cell immunotherapy for nearly 18 years. Our core product, EAL, is a multi-target cellular immunotherapy product. It has accumulated a track record of more than ten years in clinical application and has shown curative effects on various cancers. The company began EAL related research in 2006, improved cell culture systems and methods, and developed a proprietary technology platform with independent intellectual property rights for producing EAL cells. The company chose prevention of recurrence of liver cancer after surgery as a clinical indication for EAL clinical trials. We plan to submit an application to commercialize EAL in the Chinese market after the clinical trial results are statistically significant. Our product pipeline covers major categories of cellular immunotherapy products such as non-genetically-modified and genetically-modified products, as well as multi-target and single-target products. In addition to EAL, the main products under development include 6B11, CAR-T cell series, and TCR-T cell series. The core technical team consists of senior cancer immunologists, who are forward-looking and sensitive to the industry. We have established an R&D organization structure from early R&D, pre-clinical research, clinical research to commercial production and management, so that product development can advance rapidly. The company has also established the technical platform required for the development of cellular immunotherapy products, and has set up an organization and management platform for clinical trials.